Craft

AnGes

Stock Price

¥50

2024-10-29

Market Capitalization

¥12 B

2024-10-29

Revenue

¥874.1 M

FY, 2025

AnGes Summary

Company Summary

Overview
AnGes is a biopharmaceutical company specializing in R&D and practical application of genetic medicine. It provides the HGF plasmid gene therapy for the treatment of critical limb ischemia, an impairment of blood circulation in the leg. Additionally, the company develops a nucleic acid medicine that suppresses inflammation for diseases including low back pain.
Type
Public
Status
Active
Founded
1999
HQ
Ibaraki, JP | view all locations
Website
https://www.anges.co.jp/en/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

LocationsView all

6 locations detected

  • Ibaraki, Osaka HQ

    Japan

    5-chōme-12-2 Saitoasagi

  • Bethesda, MD

    United States

    10411 Motor City Dr #430

  • Fujisawa, Kanagawa

    Japan

  • Ibaraki, Osaka

    Japan

    Saitoasagi, 5-chōme-1 Saitoasagi

  • Kawasaki, Kanagawa

    Japan

    3-chōme-25-14 Tonomachi, Kawasaki-ku

  • Minato City, Tōkyō-to

    Japan

    3-chōme-5-21 Mita

AnGes Financials

Summary Financials

Revenue (FY, 2025)
¥874.1M
Gross profit (FY, 2025)
¥374.2M
Net income (FY, 2025)
(¥5.1B)
Cash (FY, 2025)
¥1.9B
EBIT (FY, 2025)
(¥5.0B)
Enterprise value
$10.2B

Footer menu